Septerna (SEPN) SVP sells 3,501 shares at $18.06 avg

Septerna, Inc. (SEPN) Form 4: An executive identified as SVP, Drug Discovery reported a sale of 3,501 shares of common stock on 11/10/2025, coded “S.” The weighted average sale price was $18.0586.

Rhea-AI Filing Summary

Septerna, Inc. (SEPN) Form 4: An executive identified as SVP, Drug Discovery reported a sale of 3,501 shares of common stock on 11/10/2025, coded “S.” The weighted average sale price was $18.0586.

The filing notes sales occurred across a price range of $18.04 to $18.16. Following the transaction, the reporting person beneficially owns 92,911 shares, held directly.

According to the footnote, this figure includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on 10/31/2025 in transactions exempt under Rule 16b-3(c).

Insider Trade Summary

Net Seller: 3,501 shares

Net Sell 1 txn

Insider Long Daniel D.

Role SVP, Drug Discovery

Sold 3,501 shs ($63K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,501	$18.0586	$63K

Holdings After Transaction: Common Stock — 92,911 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.04 to $18.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
2. F2. Includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on October 31, 2025 in transactions that were exempt under Rule 16b-3(c).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Septerna (SEPN) disclose in this Form 4?

An officer (SVP, Drug Discovery) reported selling 3,501 shares of common stock on 11/10/2025 at a weighted average price of $18.0586.

What price range were the SEPN shares sold at?

The filing states sales occurred between $18.04 and $18.16.

How many Septerna shares does the insider hold after the transaction?

The reporting person beneficially owns 92,911 shares, held directly, after the reported sale.

What transaction code is used for the sale?

The Form 4 lists transaction code S, indicating a sale of securities.

Does the beneficial ownership include ESPP purchases?

Yes. It includes 3,501 shares acquired under the 2024 Employee Stock Purchase Plan on 10/31/2025, exempt under Rule 16b-3(c).

Is more detailed trade information available?

Yes. The filer will provide full details of shares sold at each price within the $18.04–$18.16 range upon request, per the note.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/13/2025 - 08:13 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Long Daniel D.

(Last) (First) (Middle)

C/O SEPTERNA, INC.

250 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Septerna, Inc. [ SEPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Drug Discovery

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2025		S		3,501	D	$18.0586(1)	92,911(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.04 to $18.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2. Includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on October 31, 2025 in transactions that were exempt under Rule 16b-3(c).

	/s/ Ran Xiao, Attorney-in-Fact	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.